Larimar Therapeutics Inc. (LRMR) |
|
11 -0.89 (-7.49%)
|
08-14 16:00 |
|
Open: |
12.18 |
Pre. Close: |
11.89 |
|
High:
|
12.18 |
Low:
|
11 |
|
Volume:
|
4,308 |
Market Cap:
|
169M |
|
|
|
|
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its proprietary protein replacement therapy platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is based in Bala Cynwyd, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.198 - 12.259 |
12.259 - 12.31 |
|
Low:
|
10.869 - 10.929 |
10.929 - 10.978 |
|
Close:
|
10.913 - 11.006 |
11.006 - 11.083 |
|
Technical analysis |
as of: 2020-08-14 4:32:01 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 14.61 One year: 17.07 |
| Support: |
Support1: 10.35 Support2: 9.01 |
| Resistance: |
Resistance1: 12.51 Resistance2: 14.61 |
| Pivot: |
11.18 |
| Moving Average: |
MA(5): 11.22  MA(20): 11.29
MA(100): 61.00 MA(250): 103.37 |
| MACD: |
MACD(12,26): -2.01 Signal(9): -2.88 |
| Stochastic oscillator: |
%K(14,3): 67.24 %D(3): 61.73 |
| RSI: |
RSI(14): 36.02 |
| 52-week: |
High: 243.36 Low: 9.01 Change(%): -91.0 |
| Average Vol(K): |
3-Month: 2515 10-Days: 1100 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.LRMR has closed above bottom band by 38.7%. Bollinger Bands are 96.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to LRMR's normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Tue, 11 Aug 2020
Stocks That Hit 52-Week Lows On Tuesday - Benzinga
Tue, 11 Aug 2020
Form 8-K Larimar Therapeutics, For: Aug 11 - StreetInsider.com
Tue, 11 Aug 2020
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results - GlobeNewswire
Tue, 04 Aug 2020
Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference - Yahoo Finance
Tue, 28 Jul 2020
Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich's Ataxia - GlobeNewswire
Wed, 22 Jul 2020
Biohaven's Phase 3 Trial, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha
|
Financial Analysis |
| Growth |
NA |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
NA |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
NA |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NasdaqGS |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
15 |
| Shares Float (M) |
|
|
% Held by Insiders
|
|
|
% Held by Institutions
|
|
|
Shares Short (K)
|
69 |
|
Shares Short P. Month (K)
|
116 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-1.633 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-26 |
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
|
|
Price to Cash Flow
|
-6.55 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
